Key result
In patients with type 2 diabetes mellitus, the use of biguanides (OR 0.81) or thiazolidinediones (OR 0.72) was associated with a lower risk of new-onset atrial fibrillation, whereas insulin use was associated with a higher risk (OR 1.19).
Why the study?
Does the use of different classes of antihyperglycemic drugs affect the risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus?
Population
14,410 patients with type 2 diabetes mellitus from Taiwan, comprising 2,882 cases with new-onset atrial…
Comparison
Use of specific classes of antihyperglycemic drugs vs Non-users of the respective antihyperglycemic…
Design
Case-control
Authors
Loading...
These associations should not yet change T2DM prescribing; leaves open causal AF effects pending RCTs.
Case-Control (n=14,410)
Does the use of different classes of antihyperglycemic drugs affect the risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus?
Odds Ratio: 0.81 (95% CI 0.71–0.95)
p-value: p=<0.05
In patients with type 2 diabetes mellitus, the use of biguanides or thiazolidinediones is associated with a decreased risk of new-onset atrial fibrillation, while insulin use is associated with an increased risk.
Liou et al. (2018) conducted a case-control in Type 2 diabetes mellitus (n=14,410). Antihyperglycemic drugs (biguanides) vs. Non-users was evaluated on New-onset atrial fibrillation (OR 0.81, 95% CI 0.71-0.95, p=<0.05). In patients with type 2 diabetes mellitus, the use of biguanides (OR 0.81) or thiazolidinediones (OR 0.72) was associated with a lower risk of new-onset atrial fibrillation, whereas insulin use was associated with a higher risk (OR 1.19).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: